Skip to main content
. Author manuscript; available in PMC: 2022 Jul 4.
Published in final edited form as: Rev Recent Clin Trials. 2017;12(2):111–123. doi: 10.2174/1574887112666170321121250

Fig. (4).

Fig. (4).

Overall and/or disease-free survival is historically evaluated as the outcome(s) in a randomized Phase 3 trial. Traditional trial concepts on the left emphasized population-based outcomes. Personalized medicine concepts on the right, which are reflective of molecular oncology, focus on disease-related outcomes. This latter concept provides a way to determine what is driving the growth of cancer in an individual patient and to ultimately match the patient with the right targeted therapy.